A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Clinical trial NCT03280563 · COMPLETED
Trial details
- NCT number
- NCT03280563
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-22
- Primary completion
- 2024-09-26
- Enrollment
- 144
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.